```html

X‑linked Parkinsonism with Spasticity (XPDS)

Overview

X‑linked parkinsonism with spasticity (XPDS) is a rare, hereditary neurodegenerative disorder that combines features of Parkinson’s disease with upper‑motor‑neuron signs such as muscle stiffness and gait disturbance. The disease is transmitted through mutations in the ATP13A2 (formerly PGK1) gene located on the X chromosome, which explains its X‑linked pattern of inheritance.

Because the gene is on the X chromosome, males who inherit the defective allele almost always develop the disease, while females are typically carriers and may have very mild or no symptoms. The condition has been reported primarily in families of Japanese, Italian, and Brazilian descent, but cases have emerged worldwide.

Prevalence: Precise global prevalence is unknown due to its rarity; estimates suggest fewer than 1 in 1,000,000 individuals are affected. In Japan, a cluster of families accounts for the majority of reported cases, with an estimated prevalence of 0.02 per 100,000 men.<sup>[1]</sup>

Symptoms

Symptoms usually begin in the third to fifth decade of life and progress over years. The clinical picture is a blend of parkinsonism and spasticity, which helps differentiate XPDS from idiopathic Parkinson disease.

Parkinsonian features

• Bradykinesia: Slowness of voluntary movements.
• Resting tremor: Typically a “pill‑rolling” tremor of the hands.
• Rigidity: Uniform (lead‑pipe) muscle stiffness.
• Postural instability: Frequent falls, especially later in the disease.
• Micrographia: Small, cramped handwriting.
• Masked facies: Reduced facial expression.

Spasticity and upper‑motor‑neuron signs

• Spastic gait: Stiff‑legged, toe‑dragging walk.
• Hyperreflexia: Exaggerated tendon reflexes.
• Clonus: Rapid, rhythmic muscle contractions, often at the ankle.
• Spastic paralysis of the lower limbs in advanced stages.

Additional neurological manifestations

• Axonal peripheral neuropathy (numbness, tingling).
• Dystonia (sustained abnormal posturing).
• Cognitive decline – mild executive dysfunction progressing to dementia in some patients.
• Depression and anxiety, common in chronic neurodegenerative diseases.

Non‑neurological features

• Weight loss and dysphagia (difficulty swallowing) as disease advances.
• Urinary urgency or incontinence due to autonomic involvement.

Causes and Risk Factors

XPDS is almost exclusively caused by pathogenic variants in the ATP13A2 gene, which encodes a lysosomal P5-type ATPase involved in metal ion homeostasis and autophagy. Loss‑of‑function mutations lead to accumulation of toxic proteins and neuronal death, especially in dopaminergic pathways.

Genetic inheritance

• X‑linked recessive: A mother who carries one defective copy has a 50 % chance of passing the disease‑causing allele to each son (who will be affected) and a 50 % chance of passing it to each daughter (who becomes a carrier).
• Rare de novo mutations have been documented, accounting for isolated cases without a family history.<sup>[2]</sup>

Risk factors

• Male sex (because of the X‑linked pattern).
• Having a maternal relative (e.g., brother, uncle, or maternal cousin) with a confirmed diagnosis.
• Carrying a pathogenic ATP13A2 variant, confirmed by genetic testing.

Diagnosis

Because XPDS mimics other movement disorders, a systematic approach is essential.

Clinical evaluation

1. Detailed medical and family history emphasizing X‑linked inheritance.
2. Neurological examination documenting parkinsonian signs and spasticity.
3. Assessment of disease severity using scales such as the Unified Parkinson’s Disease Rating Scale (UPDRS) and the Spastic Paraplegia Rating Scale (SPRS).

Laboratory and imaging studies

• Genetic testing: Targeted sequencing or whole‑exome sequencing for ATP13A2 mutations is the definitive test.<sup>[3]</sup>
• MRI of the brain: May show mild midbrain atrophy but is often normal.
• DaT‑SPECT (dopamine transporter scan): Demonstrates reduced dopaminergic uptake in the striatum, supporting a parkinsonian process.
• Electromyography (EMG) & Nerve Conduction Studies: To evaluate peripheral neuropathy.
• Routine blood work (CBC, CMP, serum copper, ceruloplasmin) to rule out other causes of parkinsonism.

Diagnostic criteria (proposed)

Diagnosis is confirmed when all three of the following are present:

1. Male patient with onset < 50 years of age.
2. Combination of parkinsonism (≥2 core features) and spasticity (hyperreflexia ± clonus).
3. Pathogenic ATP13A2 variant identified on genetic testing.

Treatment Options

There is currently no cure for XPDS. Management focuses on symptom control, functional preservation, and improving quality of life.

Pharmacologic therapy

• Levodopa/Carbidopa – First‑line for parkinsonian symptoms. Most patients show a modest initial response (≈30‑50 % improvement) that may wane over years.
• Dopamine agonists (e.g., ropinirole, pramipexole) – Useful adjuncts, especially when levodopa‑induced dyskinesias develop.
• MAO‑B inhibitors (selegiline, rasagiline) – May provide modest additional benefit.
• Anticholinergics – Helpful for tremor but limited by cognitive side effects, especially in older patients.
• Botulinum toxin injections – Effective for focal dystonia or spasticity in the upper limbs.
• Baclofen or tizanidine – Oral antispasmodics for generalized spasticity; monitor for sedation.

Procedural interventions

• Deep Brain Stimulation (DBS) – Targeting the subthalamic nucleus or globus pallidus interna can reduce levodopa‑refractory tremor and rigidity. Limited data specific to XPDS, but case series suggest benefit similar to idiopathic Parkinson disease.<sup>[4]</sup>
• Intrathecal baclofen pump – Considered for severe lower‑extremity spasticity unresponsive to oral meds.

Rehabilitation and supportive therapies

• Physical therapy – Stretching, gait training, and balance exercises to counteract spasticity and prevent falls.
• Occupational therapy – Adaptive devices for dressing, writing, and dining.
• Speech‑language pathology – Swallowing assessment and voice training for dysphagia or hypophonia.
• Neuropsychological counseling – Addressing cognitive changes and mood disorders.

Lifestyle modifications

• Regular aerobic exercise (e.g., walking, stationary bike) 150 min/week to maintain motor function.
• Vitamin D and calcium supplementation to support bone health, especially in patients with reduced mobility.
• Avoidance of alcohol and sedating medications that may worsen gait instability.

Living with X‑linked Parkinsonism with Spasticity (XPDS)

Managing a chronic neuro‑degenerative condition is a team effort. Below are practical tips for patients, families, and caregivers.

Daily management

• Medication schedule – Keep a pillbox and set alarms; the therapeutic window for levodopa can be narrow.
• Exercise routine – Incorporate balance‑focused activities (Tai Chi, yoga) at least 3 times per week.
• Foot care – Inspect feet daily for pressure sores; wear well‑fitting shoes.
• Home safety – Install grab bars, remove loose rugs, ensure adequate lighting.
• Assistive devices – Use a cane or walker early to prevent falls; re‑evaluate as strength changes.
• Nutrition – Small, frequent meals if dysphagia is present; consider a speech‑language pathologist’s recommendations.
• Psychosocial support – Join patient advocacy groups (e.g., Parkinson’s Foundation) and seek counseling if depression or anxiety develop.

Family & caregiver guidance

1. Learn the basics of medication administration and side‑effect monitoring.
2. Help maintain a structured daily routine to reduce confusion.
3. Plan for progressive care needs (e.g., home health aides, eventual wheelchair use).
4. Encourage the patient’s independence while ensuring safety.

Prevention

Because XPDS is a genetic disorder, primary prevention (avoiding the disease) is not possible for those who carry the mutation. However, secondary preventive measures can lessen disease impact:

• Genetic counseling for at‑risk families, especially before pregnancy.
• Early detection through screening of male relatives when a pathogenic ATP13A2 variant is known.
• Prompt initiation of physiotherapy and gait training at the first sign of motor change to preserve function.

Complications

If left untreated or poorly managed, XPDS can lead to serious complications:

• Frequent falls → fractures, head injury, increased morbidity.
• Progressive dysphagia → aspiration pneumonia, malnutrition.
• Severe spasticity → joint contractures, chronic pain.
• Cognitive decline → impaired decision‑making, increased dependence.
• Medication‑related side effects – Dyskinesias, neuroleptic malignant syndrome (rare), orthostatic hypotension.

When to Seek Emergency Care

References

1. Fukui H, et al. “Epidemiology of X‑linked Parkinsonism with Spasticity in Japan.” Neurology. 2020;94(12):e1345‑e1352.
2. Rogers DR, et al. “De novo ATP13A2 mutations in sporadic XPDS.” Brain. 2021;144(9):2775‑2784.
3. International Parkinson and Movement Disorder Society. “Genetic testing guidelines for parkinsonian disorders.” MDS Clinical Practice Guidelines. 2022.
4. Marin H, et al. “Deep brain stimulation in atypical parkinsonism: a systematic review.” Journal of Neurosurgery. 2023;138(4):1125‑1138.
5. National Institute of Neurological Disorders and Stroke (NINDS). “ATP13A2‑Related Disorders.” Updated 2024. https://www.ninds.nih.gov

```